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Specialized fibroblast differentiated states underlie
scar formation in the infarcted mouse heart
Xing Fu,1,2 Hadi Khalil,1 Onur Kanisicak,1 Justin G. Boyer,1 Ronald J. Vagnozzi,1 Bryan D. Maliken,1 Michelle A. Sargent,1
Vikram Prasad,1 Iñigo Valiente-Alandi,1 Burns C. Blaxall,1 and Jeffery D. Molkentin1,3
Cincinnati Children’s Hospital Medical Center (CCHMC), Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA. 2AgCenter, School of Animal Sciences, Louisiana State University,

1

Baton Rouge, Louisiana, USA. 3CCHMC, Howard Hughes Medical Institute, Cincinnati, Ohio, USA.

Fibroblasts are a dynamic cell type that achieve selective differentiated states to mediate acute wound healing and long-term
tissue remodeling with scarring. With myocardial infarction injury, cardiomyocytes are replaced by secreted extracellular
matrix proteins produced by proliferating and differentiating fibroblasts. Here, we employed 3 different mouse lineagetracing models and stage-specific gene profiling to phenotypically analyze and classify resident cardiac fibroblast dynamics
during myocardial infarction injury and stable scar formation. Fibroblasts were activated and highly proliferative, reaching
a maximum rate within 2 to 4 days after infarction injury, at which point they expanded 3.5-fold and were maintained long
term. By 3 to 7 days, these cells differentiated into myofibroblasts that secreted abundant extracellular matrix proteins and
expressed smooth muscle α-actin to structurally support the necrotic area. By 7 to 10 days, myofibroblasts lost proliferative
ability and smooth muscle α-actin expression as the collagen-containing extracellular matrix and scar fully matured. However,
these same lineage-traced initial fibroblasts persisted within the scar, achieving a new molecular and stable differentiated
state referred to as a matrifibrocyte, which was also observed in the scars of human hearts. These cells express common and
unique extracellular matrix and tendon genes that are more specialized to support the mature scar.

Introduction

Fibroblasts are a unique cell type of mesenchymal origin that are
present in essentially all tissues and organs, where they regulate
extracellular matrix (ECM) production and acute wound healing
(1–3). In addition to regulating local fibrosis and ECM production,
fibroblasts also secrete growth factors to support tissue regeneration in coordination with inflammatory cells (4–6). In response to
injury, tissue stretching, and cytokines such as TGF-β, fibroblasts
become activated and then differentiate into a cell type referred
to as a myofibroblast. Once induced, myofibroblasts produce and
secrete greater levels of ECM proteins, including multiple types
of collagen, and they express contractile genes, such as smooth
muscle α-actin (αSMA), that underlie their ability to contract and
close a wounded area (7, 8). In addition to forming myofibroblasts,
unactivated tissue-resident fibroblasts have been reported to differentiate into endothelial cells and perhaps even tissue parenchymal cells at a low frequency (9–11), suggesting that these cells have
some degree of multilineage competency.
In most tissues or organs, injury-induced fibrosis is a transient process that typically regresses once the healing response

Related Commentary: p. 1731
Conflict of interest: The authors have declared that no conflict of interest exists.
License: This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/.
Submitted: October 20, 2017; Accepted: February 27, 2018.
Reference information: J Clin Invest. 2018;128(5):2127–2143.
https://doi.org/10.1172/JCI98215.

is finalized (4, 12–14). However, the heart is perhaps one of the
more unique organs with respect to the fibrotic response and
wound healing, as this tissue is not inherently regenerative and a
stable scar must quickly form to prevent ventricular wall rupture.
Heart disease remains the number one cause of mortality in the
Western world, with atherosclerosis and subsequent myocardial
infarction (MI) injury representing the most lethal subset of disease (15, 16). Acute MI causes rapid necrotic and apoptotic loss
of cardiomyocytes within the ischemic region, and thereafter,
the activity of fibroblasts becomes critical in buttressing the ventricular wall as the fibrotic scar forms over several days (17–20).
Previous work has shown that αSMA+ myofibroblasts are present
within the infarct area after acute MI injury (21). While multiple
cell types have been suggested as generating myofibroblasts in
the diseased heart, more recent genetic lineage–tracing analysis
has shown that tissue-resident fibroblasts of developmental epicardial origin, which make up approximately 12% of all the cells
in the adult rodent heart, are the overwhelming source for myofibroblast generation (22–25).
Despite the critical role that fibroblasts play in the diseased
heart, the field has lacked an in-depth understanding of this cell
type and its dynamics with MI injury. However, with the recent
advent of multiple genetic lineage–tracing mouse models, it is now
possible to dissect these cells and determine their phenotypic and
functional characteristics during MI injury. Here, we used fibroblast stage-specific lineage tracing along with mechanistic analysis of MI-injured mice and mRNA expression profiling to annotate
the stable differentiated states and dynamics of fibroblasts in the
heart, which defines a fibroblast state referred to as the matrifibrocyte that resides within the mature scar.
jci.org   Volume 128   Number 5   May 2018
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Results

Cardiac fibroblast proliferation following MI. To examine the proliferation dynamics of cardiac fibroblasts in response to MI, we
employed a lineage tracking system with Tcf21MCM/+;R26EGFP mice
that expresses the MerCreMer tamoxifen-regulated protein under
the control of the transcription factor 21 (Tcf21) gene locus (26)
in conjunction with a loxP site–dependent EGFP reporter that
resides within the ubiquitous Rosa26 gene locus (Figure 1A and
Supplemental Figure 1A; supplemental material available online
with this article; https://doi.org/10.1172/JCI98215DS1). We previously showed that this lineage-tracing reporter system identifies the vast majority of tissue-resident cardiac fibroblasts in the
uninjured and injured adult mouse heart (23). Here, 4-week-old
Tcf21MCM/+;R26EGFP mice were put on tamoxifen diet for 4 weeks
to specifically label all resident fibroblasts; thereafter, the mice
received an MI surgical procedure at 9 weeks of age (Figure 1B
and Supplemental Figure 1B). To quantify proliferating cells, a single dose of 5-ethynyl-2′-deoxyuridine (EdU) was given to mice for
4 hours at multiple selected time points after MI injury, followed
by heart removal and IHC examination of EdU and Ki67 staining
(Figure 1B and Supplemental Figure 1B). The data show that 1 to 2
days after MI injury, Tcf21 lineage–traced fibroblasts did not proliferate in the infarct region of the heart, although by day 3, there was
a robust induction of proliferation (Figure 1, C and E, and Supplemental Figure 1C). The border zone region showed proliferation of
Tcf21 lineage–traced fibroblasts 1 day earlier, likely because most
of the fibroblasts died within the infarct region and 1 additional
day was needed for these cells to move into the infarct from the
border zone (Figure 1, D and E). In the infarct region, fibroblasts
continued to proliferate through day 7, although proliferation in
the border zone was extinguished after day 3 (Figure 1, C–E, and
Supplemental Figure 1C). These data indicate that resident cardiac fibroblasts proliferate robustly within 2 days of MI injury, reaching a peak by 2 to 4 days, with reduced but detectable proliferation
thereafter through day 7 within the infarct.
We also analyzed fibroblast proliferation over longer periods
of time using 7 consecutive days of EdU injections in mice, followed by harvesting hearts every week for 8 additional weeks (Figure 1F). The data show that essentially all fibroblast proliferation
occurs within the first week of MI injury in the infarct and border
zone regions (Figure 1, G–I). Total fibroblast content within the
infarct region also expands by approximately 3.5-fold versus the
uninjured heart, and this expansion in fibroblast content remains
stable over 4 weeks, suggesting that newly made fibroblasts persist within the scar region long term (Figure 1J). As further quantitation, FACS analysis of EdU-labeled Tcf21 lineage–traced fibroblasts within the infarct region was also performed. As with the
IHC analysis, FACS analysis showed a peak of cardiac fibroblast
proliferation at day 3 after MI and lesser but detectable proliferation at day 7 compared with no proliferation at day 28 (Supplemental Figure 1E). Finally, lineage-traced fibroblast proliferation
rates were minimal or nonexistent within the uninjured regions of
these same hearts, such as the septum and right ventricle, at all
time points up to 4 weeks (data not shown).
The results presented above employed Tcf21-based lineage
tracing to identify cardiac fibroblasts after MI injury. We previously demonstrated that the periostin (Postn) genetic locus con2128
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taining the MerCreMer cDNA linage traces essentially all activated cardiac fibroblasts in the heart, the overwhelming majority of
which come from Tcf21+ resident fibroblasts (23). Here, we used
a knockin allele of Postn containing the β-galactosidase (LacZ)
expression cassette to track current expression from that locus.
Importantly, these same Tcf21-traced cardiac fibroblasts coexpressed the Postn locus 4 days after MI injury within the heart
(Supplemental Figure 2A). Using PostnMCM/+;R26EGFP mice, we
observed similar proliferation dynamics in Postn lineage–traced
activated fibroblasts over 4 weeks time after MI injury as compared with Tcf21 lineage–traced cells (Supplemental Figure 2,
B–E), which further validates the conclusion that activated fibroblasts can proliferate in the heart with MI injury.
Differentiation of cardiac fibroblasts to myofibroblasts after MI.
Myofibroblasts are traditionally identified by newly acquired
expression of the Acta2 gene (αSMA protein), and these cells
are known to reside within the scar region of the infarcted myocardium (21, 27), although we know little else of their dynamics.
Here, Tcf21MCM/+;R26EGFP mice were given tamoxifen for 1 month
to prelabel quiescent resident cardiac fibroblasts so that proliferation could be correlated with αSMA expression by IHC after MI
injury. Single EdU injections were again performed each day over
10 days, and mice were harvested 4 hours after each injection, as
shown in Figure 1B. Myofibroblast formation and αSMA expression were first observed in Tcf21 lineage–traced cardiac fibroblasts
in both the infarcted area and border zone 3 days after MI injury,
coinciding with peak proliferation (Figure 2, A–C). While proliferation was mostly extinguished by day 7 in the infarct area, αSMA
expression remained high through 7 days and was even partially
detectable by day 10 in these fibroblasts, but then expression was
absent by day 14 (Figure 2, A–C, and Supplemental Figure 1D).
These results indicate that myofibroblasts in the MI-injured heart
can proliferate, with a peak effect at day 3. These results also suggest that myofibroblasts are not a long-lasting differentiated state,
as by days 7 to 10 after MI, expression of αSMA was reduced, then
entirely lost in the Tcf21 lineage–traced fibroblasts.
Tcf21MCM/+;R26EGFP mice were again subjected to 7 consecutive days of EdU injections, followed by harvesting hearts every
week for 4 to 8 additional weeks, followed by αSMA IHC analysis (Figure 1F). Essentially all of the proliferating αSMA-positive
Tcf21 lineage–traced cells were identified in the first week in the
border zone and infarct region, with loss of proliferation and current αSMA expression by 2 weeks after MI, although all of the Tcf21
lineage–traced cells persisted onwards of 8 weeks (Figure 2, D–F).
Two weeks after MI, αSMA-positive cells within the border zone
and infarct region were restricted to vessels with vascular smooth
muscle (Figure 2F). Quantitation by FACS analysis also showed
αSMA expression in Tcf21 lineage–traced fibroblasts at days 3 and 7
after MI, but not at 28 days (Supplemental Figure 1E). Nearly identical results were observed with PostnMCM/+;R26EGFP mice after MI
as a means of lineage-tracing activated fibroblasts (Supplemental
Figure 2F). Approximately 90% of Postn lineage–traced activated
fibroblasts were αSMA expressing at days 4 to 7 after MI, but by
2 weeks and afterwards, proliferation and αSMA expression were
lost from these fibroblasts (Supplemental Figure 2, G and H). Taken together, these results indicate that activated fibroblasts and
myofibroblasts in the heart proliferate during the first 7 days of MI
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Figure 1. Proliferation of Tcf21 lineage–traced fibroblasts after MI. (A) Schematic of the Tcf21 genetic locus with a tamoxifen-regulated MerCreMer cDNA
cassette inserted into exon 1 (E1).The MerCreMer-containing Tcf21 locus was introduced into R26EGFP mice containing a loxP site–flanked stop cassette
upstream of EGFP to allow for Cre-dependent lineage tracing. (B) Experimental scheme whereby Tcf21MCM/+;R26EGFP mice were given tamoxifen for 4 weeks
and rested for 1 week before MI surgery. Mice were treated with a single EdU injection at the indicated time points after MI, and hearts were harvested
4 hours after each EdU injection for IHC analysis. (C–E) Quantification of EdU+ (white) and Ki67+ (red) Tcf21 lineage–traced (EGFP+) fibroblasts (green) in
infarct region (C) and border zone (D) after a single EdU injection at the indicated time points after MI by IHC and representative IHC images. The white bar
in C represents a 0 time point. (E) Nuclei are shown with DAPI (blue); these same images are shown in Supplemental Figure 1C in a larger temporal array.
(F) Experimental scheme of tamoxifen treatment of Tcf21MCM/+;R26EGFP mice before MI surgery and 7 daily EdU injections during indicated time periods after
MI. Hearts were harvested 4 hours after the last EdU injection for IHC analysis. (G–I) Quantification of EdU+ (white) and Ki67+ (red) Tcf21 lineage–traced
fibroblasts (green) in the infarct region (G) and border zone (H) after 7 daily EdU injections during the indicated time periods after MI by IHC and representative IHC images (I). Nuclei are shown with DAPI (blue). (J) Quantification of Tcf21 lineage–traced fibroblasts in the infarct region at the indicated time
points by FACS. Density of cells is presented as the number of cells per mg of infarct tissue. (C, D, G, H, and J) Data are shown as mean ± SD (n = 3). E and I
show representative images from 3 separate hearts analyzed. Scale bars: 20 μm.
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Figure 2. Differentiation of Tcf21 lineage–traced fibroblasts into myofibroblasts after MI. (A and B) Quantification of αSMA+ and EdU+ Tcf21 lineage–
traced fibroblasts in the MI region (A) and border zone (B) after a single EdU injection at the indicated time points after MI by IHC. (C) Representative IHC
images showing αSMA+ (red) and EdU+ (white) Tcf21 lineage–traced (EGFP+) fibroblasts quantified in A and B. Nuclei are shown with DAPI (blue). These
same images from C are shown in Supplemental Figure 1D in a larger temporal array. (D–F) Quantification of αSMA+ (red) and EdU+ (white) Tcf21 lineage–
traced fibroblasts in the MI region (D) and border zone (E) after 7 daily EdU injections during the indicated time periods after MI by IHC and representative IHC images (F). Nuclei are shown with DAPI (blue). (A, B, D and E) Data are shown as mean ± SD (n = 3). C and F show representative images from 3
separate hearts analyzed. Scale bars: 20 μm.
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injury, but then progress to an alternate differentiated state that
loses proliferation capacity and αSMA expression.
Apoptosis and turnover of fibroblasts in the infarcted myocardium. We observed that Tcf21 lineage–traced fibroblasts were largely lost at day 2 from the region of the heart that suffered infarction injury, but by days 3 to 4, these cells rapidly rebounded and
expanded throughout the injured area, where they persisted long
term (Figure 1E and Supplemental Figure 1C). To examine cell
death in contributing to the dynamics of fibroblasts within the MI
region, we performed TUNEL on hearts from Tcf21MCM/+;R26EGFP
mice before and after MI (Figure 3A). Apoptotic nuclei within the
infarcted area of the heart were observed at day 1 after MI; this
peaked at day 2 and then became almost undetectable by day 7
and onwards (Figure 3B). Importantly, a substantial number of
Tcf21 lineage–traced fibroblasts were TUNEL positive at day 2
after MI, but not at day 3 (Figure 3B). At day 2 after MI, most of the
TUNEL+ cardiac fibroblasts had condensed nuclei and showed a
scattered and fragmented EGFP signal (Figure 3B). We also quantified total fibroblast numbers within the infarct 4 hours or 28 days
after a wave of EdU labeling during only the first 7 days after MI
(Figure 3C). We observed that roughly 75% of Tcf21 lineage–traced
(EGFP+) fibroblasts were labeled by EdU over 7 days of injections
after MI (Figure 3, D and E). However, if these same mice labeled
with EdU over 7 days were instead harvested at day 28 after EdU
injection, the same relative number of EGFP+ cells were EdU+,
indicating that newly formed fibroblasts are stable and not turned
over in the infarct region (Figure 3, D and E). Taken together, these
results indicate that proliferating and newly activated cardiac
fibroblasts and myofibroblasts are a robust cell type that persists
in the MI-injured area.
Fibroblasts are known for their plasticity and potential ability
to transdifferentiate into other cell types, such as immune cells or
endothelial cells (9, 28). To determine whether newly generated
fibroblasts in the infarcted heart have such an ability, hearts from
the same Tcf21MCM/+;R26EGFP mice with lineage-traced fibroblasts
were subjected to IHC for CD31 (endothelial) and CD45 (leukocytes). We were unable to detect events whereby a Tcf21 lineage–
traced fibroblast converted to a CD31- or CD45-expressing cell
(Figure 3, F and G, and Supplemental Figure 3, A–C). Interestingly,
continuous low-level proliferation of CD31- and CD45-expressing
cells was observed throughout all stages that were analyzed after
MI, indicating persistence of inflammation and angiogenesis (Figure 3, F and G, Supplemental Figure 3, B and C).
Lineage tracing specifically for myofibroblasts in the heart. We
also used Acta2CreERT2;R26EGFP mice to lineage trace myofibroblasts
specifically. The Acta2CreERT2 mice contain a bacterial artificial
chromosome (BAC) transgene that expresses the tamoxifeninducible Cre-ERT2 protein within a portion of the Acta2 genomic
locus (Figure 4A) (29). Acta2CreERT2;R26EGFP mice were given tamoxifen 1 day before and immediately after MI injury for 5 days total,
after which EdU was given at select time points to measure proliferation (Figure 4B). Similarly to what occurred in PostnMCM/+;
R26EGFP mice, Acta2 lineage–traced myofibroblasts were first
observed at day 4 after MI (Figure 4, C and D). Importantly, IHC
for αSMA protein showed that essentially all Acta2 lineage–traced
fibroblasts were also positive for αSMA protein in the first 7 days,
demonstrating the high fidelity of the Acta2CreERT2;R26EGFP genetic
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approach (Figure 4, C and D). However, by 4 and 8 weeks after
MI injury, these Acta2 lineage–traced fibroblasts persisted within the infarcted region of the heart despite the complete absence
of αSMA protein expression, with only vascular smooth muscle
cells within vessels showing expression (Figure 4, C and E). With
respect to proliferation, some Acta2 lineage–traced fibroblasts
were EdU positive within the first 7 days after MI injury, but were
refractory to cell-cycle activity thereafter (Figure 4, C and D).
Again, we observed no evidence of transdifferentiation of Acta2
lineage–traced myofibroblasts into endothelial cells or leukocytes
based on CD31 and CD45 IHC (Supplemental Figure 3, D and E).
Cardiac fibroblasts in the scar have a unique differentiated state.
The lack of EdU uptake and loss of αSMA expression in fibroblasts
residing within the relatively hypoxic and high-tension scar region
of the heart suggested that these cells achieved an alternate differentiated state. To solidify these observations, we used a model in which 2 rounds of fibroblast proliferation were induced in
the mouse heart. Tcf21MCM/+;R26EGFP mice were first treated with
tamoxifen to label all fibroblasts with EGFP; then MI injury was
performed, followed 4 weeks later by placement of s.c. osmotic pumps loaded with angiotensin II (Ang II) and phenylephrine
(PE). Infusion of these 2 agonists is known to activate fibroblasts in
the heart and cause proliferation with ensuing interstitial fibrosis
(30, 31) (Figure 5A). Remarkably, the Tcf21 lineage–traced fibroblasts within the MI scar region were refractory to subsequent Ang
II/PE–induced EdU incorporation and proliferation, while resident fibroblasts in the remainder of the heart, such as the septum,
readily proliferated (Figure 5, B and C). Analysis of Ki67 expression as an indicator of proliferation showed a profile similar to that
of EdU (Figure 5C). We also sorted Tcf21 lineage–traced (EGFP+)
fibroblasts from the uninjured heart versus the infarct scar region
28 days after MI for assessment of proliferation in culture, with
and without TGF-β stimulation. Under these conditions, 6 hours
of EdU treatment labeled significantly more Tcf21 lineage–traced
fibroblasts isolated from the uninjured heart compared with the
scarred region, with or without TGF-β stimulation (Figure 5, D and
E). However, TGF-β treatment was equally efficient in promoting
αSMA stress fiber formation in either population of isolated fibroblasts (Figure 5F). Taken together, these results suggest that fibroblasts within the infarcted scar region have unique properties that
could represent a previously unappreciated differentiated state.
Myofibroblasts stabilize the scar before the collagen scar forms.
Myofibroblasts within the infarcted region of the heart only
express αSMA protein from approximately days 3 to 10 after
MI, which was an unexpected observation, given that these lineage-traced cells persist for what appears to be the life of the scar.
To better understand the dynamics of the cardiac myofibroblast
after MI injury, we conducted a series of histological and mechanistic experiments. We first documented the progression of postMI ventricular remodeling and ECM architecture to compare
against fibroblast phenotyping. Picrosirius red staining of cardiac
histological sections showed a progressive accumulation of collagen within the infarcted area over the first 6 days after MI and,
thereafter, a progressive condensation of the collagen scar and
an increase in its complexity (Figure 6A and Supplemental Figure 4A). Between 1 and 2 weeks, the greatest increase in collagen
complexity was observed, which was also the time when myofijci.org   Volume 128   Number 5   May 2018
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Figure 3. Apoptosis and turnover of Tcf21 lineage–traced fibroblasts after
MI. (A) Experimental scheme of tamoxifen treatment of Tcf21MCM/+;R26EGFP
mice before MI. Hearts were harvested at the indicated time points after
MI for TUNEL staining. (B) Representative TUNEL staining (red) images
from 3 separate hearts analyzed showing apoptotic Tcf21 lineage–traced
(EGFP+) fibroblasts after MI. Nuclei are shown with DAPI (blue). The inset
shows a higher magnification (×8) image of a TUNEL+ EGFP+ cell. (C) Experimental scheme of tamoxifen treatment of Tcf21MCM/+;R26EGFP mice before
MI followed by 7 daily EdU injections during the first week after MI. Hearts
were then harvested 4 hours and 28 days after the last EdU injection for
IHC analysis. (D and E) Quantification (D) of EdU+ (white) Tcf21 lineage–
traced (EGFP+) fibroblasts in the infarcted area at 4 hours and 28 days
after the last injection of 7 daily EdU injections. (E) Nuclei are shown with
DAPI (blue), and αSMA (red) was stained to show myofibroblast identity.
Data are shown as mean ± SD (n = 3 hearts analyzed). Two-tailed t test
showed no significance. For E, representative IHC images are shown from
3 separate hearts analyzed. (F) Representative IHC images from 3 separate
hearts analyzed showing EdU+ (white) CD31+ endothelial cells (red) versus
Tcf21 lineage–traced fibroblasts (EGFP+) in hearts before MI and within
infarct region at day 4 and day 10 after MI 4 hours after a single EdU
injection. (G) Representative IHC images from 3 hearts analyzed showing
EdU+ (white) CD45+ leukocytes (red) versus Tcf21 lineage–traced fibroblasts
(EGFP+) in hearts before MI and within infarct region at day 4 and day 10
after MI 4 hours after a single EdU injection. Scale bars: 20 μm.

broblasts lost their αSMA expression (Figure 6A and Supplemental
Figure 4A). Microscopic histologic analysis for collagen III (Col3)
showed that between days 4 and 10, the collagen-rich basal lamina
that previously surrounded each cardiomyocyte became progressively thicker and reorganized from circular structures into long
continuous strands of collagen (Figure 6B, Supplemental Figure
4B, and Figure 7). The resident fibroblasts previously labeled with
the Tcf21MCM/+;R26EGFP alleles initially localized around the basal lamina with long processes, but by day 10 and onwards, they
reorganized commensurate with the loss of αSMA expression into
more linear-shaped cells lacking processes (Figure 6B, Supplemental Figure 4B, and Figure 7). These observations suggest that
αSMA expression might underlie a structural role within the first
7 days after MI injury by fully surrounding and connecting all the
“ghost” basal lamellar regions with a continuous network of cellular αSMA filaments (Figure 7).
To examine this concept of a cellular support network more
directly, we used 2 different methods to destabilize maturing
collagen within the infarct region, both of which resulted in prolonged αSMA expression and the traditional myofibroblast phenotype (Figure 8, A–E, and Supplemental Figure 4, C and D). The
first method involved treating mice after MI with β-aminoproprionitrile (BAPN), an inhibitor of lysyl oxidase (LOX) that antagonizes collagen maturation (32, 33). This treatment maintained αSMA
expression within the Tcf21 lineage–traced fibroblasts through
14 days after MI, while αSMA expression in hearts not treated
with BAPN only showed αSMA in vessels (Figure 8, A and B). We
also previously showed that deletion of the Postn gene rendered
hearts with immature scars that ruptured as well as with less crosslinked and complex collagen (34–37). Here, we generated Postnnull mice by crossing 2 PostnMCM/+ alleles together along with the
R26EGFP lineage–tracing allele. PostnMCM/MCM;R26EGFP or control
PostnMCM+;R26EGFP mice were given MI at 8 weeks of age, followed
by tamoxifen administration to label activated fibroblasts, after
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which the hearts were harvested at day 14 (Figure 8C). Importantly, PostnMCM/MCM mice showed loss of periostin protein expression
in the infarct region (Figure 8D) along with reduced Col1 and
Col3 within the infarct (Supplemental Figure 4D).The data again
showed persistent αSMA expression in fibroblasts from Postn-null
mice within the MI region at 14 days, while controls showed almost
complete loss of αSMA expression in these fibroblasts (Figure 8E).
Taken together, these results suggest that loss of the myofibroblast
phenotype is associated with infarct scar maturation, such that the
differentiated state of these cells with αSMA expression persists
as a likely attempt to maintain ventricular wall integrity until the
collagen is fully supportive.
Gene expression defines fibroblast-differentiated states after MI.
We next performed mRNA profiling to gain insight into molecular signatures of gene expression that might underlie the phenotypic stages of fibroblasts we observed in the post-MI heart.
Tcf21MCM+;R26EGFP mice were used so that EGFP+ fibroblasts could
be directly FACS isolated for mRNA extraction without culturing.
Tcf21 lineage–traced fibroblasts were obtained from adult uninjured hearts and compared against cells isolated from the infarcted
regions of hearts at 3 days, 7 days, 2 weeks, and 4 weeks, revealing
some 5,000 differentially expressed genes (Figure 9A). Bioinformatic analysis showed the greatest number of gene-expression
clusters at 3 days after MI injury compared with fibroblasts from
uninjured hearts, followed thereafter by 7 days after MI injury,
while 2 weeks and 4 weeks after MI injury showed the least number
of clusters of differentially expressed genes compared with fibroblasts from the uninjured heart (Figure 9A). Indeed, Venn diagram
analysis showed 2,013 uniquely differentially expressed genes
between fibroblasts from the uninjured heart and 3 days after MI
injury and 1,029 at day 7 after MI injury (Figure 9B). However, by
2 and 4 weeks after MI injury, there were only 497 and 355 uniquely changed genes that were significant versus those in uninjured
fibroblasts, respectively (Figure 9B). Moreover, only 690 (86+604)
significantly changed genes were in common between the 2- and
4-week post-MI fibroblasts compared with the 3-day post-MI activated fibroblasts (Figure 9B). These results suggest that fibroblasts
from the 3-day injured MI region have the greatest differences in
gene expression compared with any other time point and that by
4 weeks after MI injury, these cells are most highly related to the
uninjured state, although they clearly maintain a large number of
differential clusters (Figure 9, A and B). Importantly, 604 genes
were always differentially expressed between fibroblasts from all 4
stages of injury with uninjured fibroblasts, showing that they are all
still fundamentally the same cell lineage (Figure 9B).
Genes were also clustered into key biologic features of the
fibroblast, such as proliferation, cell migration, cytoskeleton,
ECM and ECM modification, apoptosis inhibitor, and bone and
cartilage signatures (Figure 10A). Consistent with our phenotypic data, proliferation- and migration-regulating genes were most
highly induced at day 3 after MI in Tcf21 lineage–traced fibroblasts,
but were then extinguished by 2 and 4 weeks (Figure 10, B and C).
Cytoskeletal- and ECM-modifying genes were also most highly
induced at days 3 and 7, but then downregulated by 4 weeks after
MI (Figure 10, D and F), while traditional fibroblast marker genes
and ECM genes remained expressed at essentially all time points
(Figure 10, E and I). However, we observed that Tcf21 and Pdgfrα
jci.org   Volume 128   Number 5   May 2018
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Figure 4. Lineage tracing of myofibroblasts in Acta2CreERT2;R26EGFP mice. (A) Schematic of the Acta2 BAC with a tamoxifen-regulated CreERT2 cDNA
cassette inserted into exon 1, and mice containing this transgene were crossed with R26EGFP reporter mice containing a loxP site–flanked stop cassette
upstream of EGFP to allow for Cre-dependent lineage tracing. (B) Experimental scheme whereby Acta2CreERT2;R26EGFP mice were given tamoxifen through
daily i.p. injections from day –1 to day 4 after MI. Mice were treated with a single EdU injection at the indicated time points after MI, and hearts were
harvested 4 hours afterward for IHC analysis. (C and D) Representative IHC images from 3 hearts analyzed showing αSMA protein (red) and EdU+ (white) in
αSMA lineage–traced (EGFP+) fibroblasts in the infarct region after a single EdU injection at the indicated time points after MI (C) and quantification (D).
Nuclei are shown with DAPI (blue). Data are shown as mean ± SD (n = 3). Scale bars: 20 μm. (E) Representative IHC images from 3 separate hearts analyzed
showing αSMA lineage–traced (EGFP+) fibroblasts and expression of αSMA protein (red) in the infarct region and border zone at 7 days and 8 weeks after
MI. Nuclei are shown with DAPI (blue). Scale bars: 200 μm.

were most highly expressed in quiescent fibroblasts and became
downregulated with fibroblast activation (Figure 10I). Apoptosis
inhibitory genes were also induced by day 7 and onwards, perhaps providing protection of these cells in the relatively hypoxic
environment of the scar (Figure 10H). Finally, we also identified a
number of secreted genes that were differentially expressed (Supplemental Figure 5), but across the different “fibroblasts stages,”
we did not observe a change in inflammatory pathway genes or a
clustering of immune response genes (data not shown).
While the most gene changes were observed at 3 days after MI
injury versus those in fibroblasts from the uninjured heart, bioinformatic pathway ontology analysis showed a remarkable profile
of up- and downregulated genes in fibroblasts isolated from the
post-MI heart at 4 weeks that appeared to represent an entirely
unique differentiated state (Supplemental Table 1). Most notable
among these pathway gene changes was an induction of genes
underlying bone, connective tissue, cartilage, and tendon devel2134
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opment or processing (Supplemental Table 1). Selected genes
from this pathway signature at 2 and 4 weeks after MI showed
an induction of cartilage oligomeric matrix protein (Comp, also
known as thrombospondin 5) and chondroadherin (Chad) and
Cilp2 (Figure 10G). IHC staining confirmed the specific expression of Comp and Chad in the infarct region at 4 weeks after MI,
with little to no protein expression observed at day 7 when myofibroblasts are present (Figure 11, A and B). Importantly, Comp
and Chad expression were also identified in the fibrotic area of
human heart samples from ischemic patients that had left ventricular (LV) assist devices placed, but not within unscarred or
uninjured heart tissue (Figure 11C). Also of note, αSMA expression was not observed in vimentin+ cells (fibroblasts) within the
mature scarred region of human hearts, although nearby vessels
showed αSMA expression in vascular smooth muscle cells, presumably suggesting that myofibroblasts are also a transient cell
type in the scar of the human heart (Figure 11C).
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Figure 5. Proliferation potential of Tcf21 lineage–traced fibroblasts residing in stable scar. (A) Experimental scheme whereby Tcf21MCM/+;R26EGFP mice
previously treated with tamoxifen were subjected to MI and then treated with Ang II/PE through osmotic pump 4 weeks after MI. Mice were treated with
EdU through daily i.p. injections for 6 days starting at day 2 after pump implantation, and hearts were harvested 4 hours after the last EdU injection for
IHC analysis. (B and C) Quantification (B) and representative IHC images from 3 hearts analyzed (C) of EdU+ (white) and Ki67+ (red) Tcf21 lineage–traced
(EGFP+) fibroblasts in the infarct region and septum of hearts from Tcf21MCM/+;R26EGFP mice that received treatment as shown in A. Nuclei are shown with
DAPI (blue). Scale bars: 20 μm. (D and E) Quantification (D) and representative immunocytochemistry from 3 separate experiments (E) of EdU+ (white)
Tcf21 lineage–traced (EGFP+) fibroblasts isolated from uninjured hearts and the infarct region of hearts 4 weeks later. EdU was given for 6 hours with and
without TGF-β stimulation. Scale bars: 200 μm. (F) Representative immunocytochemistry images from 3 separate experiments showing αSMA stress
fibers (red) in Tcf21 lineage–traced fibroblasts isolated from uninjured hearts and the infarct region of hearts 4 weeks after MI. Cells were also treated with
TGF-β for 3 days. Scale bars: 10 μm. (B and D) Data are shown as mean ± SD (n = 3). **P < 0.01, ***P < 0.0001, 2-tailed t test.

Secondary cryoinjury and cell ablation within the scar exacerbates heart failure. To study the potential function of matrifibrocytes, cryoinjury was applied to the infarct region 8 weeks after the
initial surgical MI procedure as a means of killing these cells (Supplemental Figure 6A). Two weeks after cryoinjury, the number
of Acta2 lineage–traced matrifibrocytes was efficiently reduced,
although the vascular cell content was also reduced (Supplemental Figure 6B). IHC showed that the ECM in the cryoinjured infarct
region was mildly disrupted with reduced Col3 content and organization (Supplemental Figure 6B). Heart function was also significantly reduced after the cryoinjury procedure compared with that
in sham controls, which remained the same as before cryoinjury
(Supplemental Figure 6, C and D, P < 0.05). These data indirectly

suggest that matrifibrocytes could have a functionally important
role in maintaining the integrity of the mature scar.

Discussion

Despite their importance in cardiac disease states, surprisingly
few studies are present in the literature that interrogate the cellular dynamics and function of fibroblasts in the heart with MI
injury. This is likely attributable to the fact that the field previously
lacked rigorous genetic approaches to reliably identify fibroblasts
and their various differentiated stages in the heart. Here, we used 3
different lineage-tracing Cre-expressing lines to definitively identify quiescent resident cardiac fibroblasts, newly activated cardiac
fibroblasts, or myofibroblasts for in-depth analysis as to how these
jci.org   Volume 128   Number 5   May 2018
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Figure 6. Temporal maturation of the scar in the mouse heart. (A) Representative Picrosirius red staining images of WT heart histological cross-sections taken in bright-field mode or under polarized light for birefringence detection at the indicated time points showing the progression of fibrosis and
collagen maturation after MI injury. Scale bars: 1 mm. Representative images are shown from 3 hearts analyzed at each time point. (B) Representative
IHC images showing morphological changes in Col3 (red) along with Tcf21 lineage–traced (EGFP+) fibroblasts from the infarct region of hearts from
Tcf21MCM/+;R26EGFP mice at indicated time points. Nuclei are shown with DAPI (blue). Scale bars: 20 μm. Representative images are shown from 3 hearts
analyzed at each time point.

cells proliferate and differentiate in the heart following MI injury. We observed that fibroblasts and cardiomyocytes are equally
killed within the ischemic region, but proliferating fibroblasts in
the border zone at day 2 invade the necrotic area, where by days 3
to 4, they achieve maximal proliferation and coverage within the
developing scar. The proliferation of activated fibroblasts or myofibroblasts remains high for another 2 to 3 days within the infarct
region, but is dampened 1 day sooner within the border zone
region. Unexpectedly, proliferation of activated fibroblasts and
myofibroblasts is almost entirely extinguished by 7 days after MI
injury, which is consistent with a very recent report (38), although
dynamic remodeling of the scar area with increased collagen complexity continues through week 2. Remarkably, mechanical stress
itself robustly induces the differentiation of quiescent fibroblasts
into αSMA-expressing myofibroblasts (39). However, the stiffness
and mechanical tension properties of the infarct scar gradually
increase after MI (40), despite the fact that the myofibroblast differentiated state is rapidly lost by days 7 to 10 in this region.
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Another interesting observation is that myofibroblasts with
abundant αSMA expression proliferate (days 3 to 6), which is consistent with a previous report on the infarcted heart (21). However,
previous studies suggested that myofibroblasts within the stabilized infarct scar were cleared by apoptosis (41, 42), although we
observed that lineage-traced fibroblasts (Tcf21-MCM), activated
fibroblasts (Postn-MCM), and myofibroblasts (Acta2-CreERT2)
persist within the scar long term and are highly resistant to apoptosis. The discordance is likely because the approaches by Takemura et al. and Zhao et al. (41, 42) were not based on lineage tracing
and because loss of αSMA expression might have been incorrectly
interpreted as cell loss. Finally, we observed that fibroblast proliferation resulted in an approximate 3.5-fold total expansion of
these cells within the infarction area compared with the uninjured
heart and that this enhanced cell content was maintained long
term within the scar without cell turnover.
Another interesting observation of the current study is that
αSMA expression is limited to the first 7 to 10 days of MI injury
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Figure 7. Model of MI injury–dependent cardiac fibroblast states. Model showing the different states of cardiac fibroblasts at different post-MI stages.
In uninjured heart, cardiac fibroblasts reside within the interstitial space, but after MI injury, they become maximally activated by 2 to 4 days, and they
elongate and begin to express αSMA. By days 4 to 7, the myofibroblast differentiated state is maximal, with high levels of αSMA protein in elongated
processes within these cells. Finally, these fibroblasts stop proliferating and lose αSMA expression as they further differentiate into the matrifibrocyte by
day 10 and onwards within the scar region.

within myofibroblasts, indicating that this differentiated state
is rather transient in the scar area. Myofibroblasts with αSMA
expression have been shown to underlie tissue regeneration in the
lung and skin, and αSMA expression decreases as the regeneration
process is completed (9, 43, 44). We have previously shown that
deletion of activated fibroblasts from the infarcted mouse heart
using PostnMCM/+;R26DTA alleles resulted in much greater lethality due to ventricular wall rupture, indicating that activated fibroblasts and myofibroblasts are required for acute ventricular wall
healing (23). Even mice with deletion of the Postn gene, which is
needed for collagen maturation (34), exhibit a heart significantly
more susceptible to ventricular wall rupture in the first week after
MI injury (37, 45). Thus, activated fibroblasts and myofibroblasts
are critical players in cardiac wound healing after MI injury.
We previously showed that myofibroblasts in the heart can
dedifferentiate and revert back to an “uninjured” state after a
cardiac stress response resolves, such as with Ang II/PE agonist
infusion and then its removal (23). A similar response is also
observed in regenerative tissues such as lung, in which an injury
is fully resolved and fibrosis typically reverts back to preinjury
status (9). In comparison, MI injury requires the persistence of a
stable star because the adult mammalian heart is not significantly
regenerative. This stable scar environment houses the more highly
differentiated fibroblast stage referred to here as the matrifibrocyte (Figure 7). These cells share some gene signatures with chondrocytes and osteoblasts, which are adapted to highly collagenous
environments and for building and maintaining cartilage and
bone ECM (46–48). However, extensive biologic pathway analysis of the 5,000 differentially expressed and clustered genes suggests that these cells are entirely unique and are not chondrocytes,
osteoblasts, osteoclasts, tendon cells, or myofibroblasts, although
they are most closely related to quiescent fibroblasts (Supplemental Table 1, and see Figure 9, A and B). The expression of ECM and
ECM-modifying genes, including some genes typically observed
in tendon, bone, and cartilage, suggests that matrifibrocytes

within the scar are more highly specialized for this environment.
Matrifibrocytes within the scar also resist new rounds of proliferation when challenged with Ang II/PE, yet fibroblasts in the uninjured regions of the heart show abundant proliferation.
To fully explore the functional role of these cells, we first
attempted to selectively kill them using a Rosa26-loxP-DTR-loxP
approach in conjunction with the PostnMCM allele. Using these
alleles, expression of the human diphtheria toxin receptor was
induced on all activated fibroblasts, which we later attempted to
kill coincident with infusion of diphtheria toxin. Importantly the
mouse is normally resistant to diphtheria toxin unless the human
receptor is expressed (49). However, for unknown technical reasons, this system was not effective in killing matrifibrocytes in the
scar (data not shown); hence, the less specific cryoinfarction model was necessary. This later model did effectively kill matrifibrocytes in the scar and was suggestive of a potential important functional role for these cells in maintaining the integrity of the mature
scar, although vascular cells in the scar were also killed by this procedure and could have also contributed to the reductions in scar
integrity. Finally, the human scar also appears to contain matrifibrocytes based on loss of αSMA expression in vimentin+ cells and
attainment of Chad and Comp expression, suggesting that these
cells warrant further mechanistic investigation as another potential strategy for positively affecting post-MI scar formation and
long-term scar remodeling with heart failure.

Methods

Human samples. Human myocardial LV free wall tissue was obtained
from patients of ischemic etiology (n = 3) during LV assist device
implantation. Nonfailing LV free wall tissue was obtained from
donors deemed unsuitable for transplant with no cardiac dysfunction. Tissue was freshly obtained and embedded in OCT compound
and frozen for cryosectioning.
Mice. Mouse lines used in this study were as follows: Postn-MerCreMer (23), Tcf21-MerCreMer (26), Acta2-CreERT2 (29), Postn-LacZ
jci.org   Volume 128   Number 5   May 2018
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Figure 8. Effect of ECM maturation on αSMA expression in myofibroblasts. (A and B) Representative IHC images (A) and quantitation (B) of αSMA+ (red)
Tcf21 lineage–traced (EGFP+) fibroblasts from the infarct region of hearts from Tcf21MCM/+;R26EGFP mice treated with BAPN or PBS as a control (Cont.). Nuclei
are shown with DAPI (blue). Scale bars: 20 μm. Data are shown as mean ± SD (n = 3). ***P < 0.0001, 2-tailed t test. (C) Experimental scheme of tamoxifen
treatment of PostnMCM/MCM;R26EGFP and PostnMCM/+;R26EGFP mice from day 2 to day 3 after MI by daily i.p. injections. Hearts were then harvested at 2 weeks after
MI. (D) Representative IHC images from 3 separate hearts analyzed for Postn protein expression within the infarct region of hearts from PostnMCM/+;R26EGFP
mice versus PostnMCM/MCM;R26EGFP mice 2 weeks after MI. Nuclei are shown with DAPI (blue). Scale bars: 20 μm. Postn lineage–traced cells (EGFP+) cells are also
shown. (E) Representative IHC images from 3 separate hearts analyzed showing αSMA+ (red) and Postn lineage–traced (EGFP+) fibroblasts in the infarct region
of hearts from PostnMCM/+;R26EGFP mice and PostnMCM/MCM;R26EGFP mice 2 weeks after MI. Nuclei are shown with DAPI (blue). Scale bars: 50 μm.

(Jackson Laboratories, stock no. 024186), and FVB.Cg-Gt(ROSA)
26Sortm1(CAG-EGFP)Glh/J (50). Postn-MerCreMer mice, Tcf21-MerCreMer mice, and Acta2-CreERT2 mice were crossbred with FVB.
Cg-Gt(ROSA)26Sortm1(CAG-EGFP)Glh/J mice to obtain Tcf21MCM/+;
R26EGFP mice, PostnMCM/+;R26EGFP mice, and Acta2CreERT2;R26EGFP mice,
respectively. Tcf21MCM/+;R26EGFP mice were crossbred with Postn-LacZ
mice to obtain Tcf21MCM/+;R26EGFP;PostnLacZ/+ mice.
Antibodies and biologics. Antibodies against EGFP (catalog
ab13970 and ab290), β-galactosidase (catalog ab9361), Col1 (catalog ab34710), vimentin (catalog ab45939), and Col3 (catalog ab7778)
were purchased from Abcam. Anti-αSMA antibody (catalog A2547),
anti-Chad antibody (catalog HPA018241), Ang II (catalog A9525),
and PE hydrochloride (catalog P6126) were purchased from SigmaAldrich. Anti-Ki67 antibody (catalog 9129S) was purchased from Cell
Signaling Technology. Anti-periostin antibody (catalog NBP1-30042)
was purchased from Novus Biologicals. Anti-CD45 antibody (catalog
14-0451-82) was purchased from eBioscience. Anti-CD31 antibody
(catalog 553370) was purchased from BD Bioscience. Anti-Comp antibody (catalog 13641-1-ap) was purchase from ProteinTech. Goat antimouse IgG2a Alexa Fluor 568 (catalog A-21134), goat anti-chicken
Alexa Fluor 488 (catalog A-11039), goat anti-chicken Alexa Fluor 568
(catalog A-11041), goat anti-rabbit Alexa Fluor 488 (catalog A-11008),
and goat anti-rabbit Alexa Fluor 568 (catalog A-11036) secondary antibodies were purchased from Life Technologies. TGF-β (catalog 101b1-010) was purchased from R&D Systems. EdU (catalog sc-284628A)
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was purchased from Santa Cruz Biotechnology Inc. Collagenase D
(catalog 11088866001) and Dispase II (catalog 10165859001) were
purchased from Roche Diagnostics.
Animal procedures. To induce activity of the MerCreMer or the
CreERT2 protein, mice were fed a diet containing 400 mg/kg tamoxifen citrate (Envigo, TD.55125) or were treated with tamoxifen (MilliporeSigma, T5648) dissolved in corn oil through i.p. injections at
a dosage of 75 mg/kg body weight/d. The duration of treatment is
indicated within Figure 1, A and F; Figure 3, A and C; Figure 4B; Figure 5A; and Figure 8C. MI was induced in mice via permanent surgical
ligation of the left coronary artery (51). Briefly, mice were anesthetized
using isoflurane and a left lateral thoracotomy was performed. The left
coronary artery was identified and ligated just below the left atrium.
For Ang II/PE treatment, micro-osmotic pumps (Azlet, model 1002)
were inserted s.c., delivering a combination of 1.5 μg/g/d Ang II (MilliporeSigma, A9525) and 50 μg/g/d PE hydrochloride (MilliporeSigma,
P6126). Cryoinjury was induced in mice via applying a liquid nitrogen–cooled metal probe (3 mm × 3 mm) to the surgically exposed prior
infarct region of the heart for 3 seconds. For LOX inhibition studies,
mice were treated with BAPN through i.p. injection at a dosage of 500
mg/kg body weight/d from 1 day before MI to day 14 after MI. Mice
treated with PBS were used as vehicle control. Echocardiography was
performed in M-mode using a Hewlett Packard SONOS 5500 instrument equipped with a 15 MHz transducer as described previously (52).
For pain management related to surgical procedures, mice were given
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Figure 9. Gene-expression patterns of fibroblast stages in the MI
injured heart. (A) Heatmap showing approximately 5,000 genes differentially expressed with cluster analysis among quiescent Tcf21 lineage–
traced (EGFP+) fibroblasts isolated from the uninjured LV or the MI region
3 days, 7 days, 2 weeks, and 4 weeks after injury. Individual biological
replicates are shown. Individual samples were clustered and connected
by Transcriptome Analysis Console based on their similarity in geneexpression patterns. (B) Venn diagram showing numbers and overlapping
genes that were differentially expressed between Tcf21 lineage–traced
(EGFP+) fibroblasts isolated from the uninjured LV versus the other 4
sample groups of isolated fibroblasts from the MI region 3 days, 7 days, 2
weeks, or 4 weeks after injury.

a single postoperative dosage of buprenorphrine-sustained release formula (3.25 mg/kg body weight) by s.c. injection at 0.05 to 0.1 mg/kg.
EdU in vivo fibroblast proliferation assay. Mice were treated with
EdU at a dosage of 50 mg/kg body weight through i.p. injections. Four
hours after EdU injections, mice were sacrificed and heart samples
were collected. EdU detection was carried out after IHC staining using
the Click-iT Plus Alexa Fluor 647 Picolyl Azide Toolkit (C10643) from
Thermo Fisher Scientific.
FACS. Heart tissue was digested as previously described, with modifications (53). Briefly, heart tissue was minced and digested in DMEM
containing 0.75 U/ml collagenase D (Roche, 11088866001), 1.0 U/ml
Dispase II (Roche, 10165859001), and 1 mM CaCl2 at 37°C for 40 minutes. The slurry was then passed through a 100 μm cell strainer and then
a 40 μm cell strainer. Cells were collected by centrifugation at 350 g for
10 minutes. The cell pellet was then resuspended in PBS. Tcf21 lineage–
traced EGFP+ cardiac fibroblasts were sorted on FACSaria II (BD Biosciences). Gates were made based on WT EGFP– control. Sorted EGFP+
cardiac fibroblasts were used for RNA analysis. For FACS involving
αSMA and EdU staining, heart tissue was removed from mice 4 hours
after EdU injection and digested and sorted as described above. Sorted
EGFP+ cardiac fibroblasts were fixed in 100% ice-cold methanol for 30
minutes, rinsed in PBS, and blocked in PBS with 1% BSA for 20 minutes
at room temperature. EdU staining was performed using Click-iT Plus
Alexa Fluor 647 Picolyl Azide Toolkit (C10643) from Thermo Fisher
Scientific, which was followed by incubation with anti-αSMA eFluor 570
(eBioscience 41-9760-82, 1:50) for 1 hour at room temperature. Cells
were then rinsed in PBS and analyzed on FACSCanto (BD Biosciences).
Undifferentiated NIH 3T3 cells and Tcf21 lineage–traced EGFP+ cardiac fibroblasts sorted from uninjured hearts were processed at the same
time and were used as negative control for gating.
Cell culture. FACS-sorted Tcf21 lineage–traced fibroblasts were
resuspended in growth medium composed of DMEM with 10% bovine
growth serum and 1% of an antibiotic mixture containing 10,000 U/
ml penicillin, 10 mg/ml streptomycin, and 25 μg/ml amphotericin B.
Resuspended fibroblasts were seeded on 8-chamber slides at a density

of 5 × 103 cells/well. Cells were grown at 37°C with 5% CO2. For EdUbased proliferation assay, cells were cultured in the same growth medium supplemented with 10 μM EdU for 6 hours and with or without
TGF-β stimulation (10 ng/ml) starting at 60 hours after cell isolation.
For induction of myofibroblast differentiation, Tcf21 lineage–traced
fibroblasts were cultured in the same growth medium supplement
with TGF-β (10 ng/ml) for 48 hours.
Affymetrix microarray and bioinformatics. Total RNA was extracted from 50,000 FACS-sorted Tcf21 lineage–traced fibroblasts using
the miRNeasy Micro Kit (217084, QIAGEN). Microarray analysis was
carried out via the Gene Expression Core Facility (CCHMC) using the
Affymetrix Clariom S platform. Differential gene expression between
samples was determined via bioinformatics analyses of resultant data
(CEL files) using the Transcriptome Analysis Console (Applied Biosystems; ver. 4.0.0.25), the Clariom_S_Mouse TAC Configuration file
(ver. 1), and the iPathwayGuide (Advaita Bioinformatics). All original
microarray data were deposited in the NCBI’s Gene Expression Omnibus database (GEO GSE111059).
Immunocytochemical staining. FACS-sorted Tcf21 lineage–traced
fibroblasts grown on multiple-chamber slides were fixed in 4% PFA
for 10 minutes, rinsed 3 times in TBS with 0.1% Triton X-100, incubated in blocking buffer (TBS, 0.1% Triton X-100, and 3% BSA), and
then incubated with primary antibodies diluted in blocking buffer at
4°C overnight. Cells were then rinsed in TBS with 0.1% Triton X-100
3 times and stained with corresponding secondary antibodies diluted
in blocking buffer for 1 hour at room temperature. Stained slides were
then rinsed and mounted in a mounting medium containing DAPI
(Vector Laboratories). Images were taken using an inverted Nikon A1R
confocal microscope using NIS Elements AR 4.13 software. Primary
antibodies and dilutions used in immunocytochemical staining (ICC)
included anti-EGFP antibody (Abcam ab13970, 1:200) and anti-αSMA
antibody (MilliporeSigma A2547, 1:200). Secondary antibodies and
dilutions used in ICC included goat anti-mouse IgG2a Alexa Fluor 568
(Life Technologies A-21134, 1:500) and goat anti-chicken Alexa Fluor
488 (Life Technologies A-11039, 1:500).
jci.org   Volume 128   Number 5   May 2018
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Figure 10. Changes in gene-expression states in the cardiac fibroblast
after infarction injury. (A) Heatmap
of selected gene-expression categories and individual genes from Tcf21
lineage–traced fibroblasts isolated from
the uninjured heart or the infarct area
of hearts 3 days, 7 days, 2 weeks, and 4
weeks after MI (assayed with Affymetrix microarrays). (B–I) Bar graphs show
mRNA expression levels of selected
cell proliferation–related genes (B), cell
migration–related genes (C), cytoskeleton-related genes (D), ECM protein
genes (E), ECM modification genes (F),
bone and cartilage–related genes (G),
apoptosis inhibitor genes (H), and fibroblast marker genes (I) in the different
sample groups. Data were normalized to
quiescent Tcf21 lineage–traced fibroblasts isolated from uninjured hearts. n =
3 (uninjured, 3 d MI, 7 d MI, and 4 wk MI),
n = 2 (2 wk MI). Different letters (a, b, c,
d, e) above the bars indicate significant
differences (P < 0.05) by 1-way ANOVA
and Tukey’s post hoc analysis between
Tcf21 lineage–traced fibroblasts isolated
at different time points in each panel.
Bars denoted by the same letter indicate
lack of significant difference within that
panel, while all bars that have different
letters are significantly different from
each other.

IHC staining. Mouse heart samples were fixed in 4% paraformaldehyde for 3.5 hours, rinsed in PBS for 30 minutes, and immersed in
PBS containing 30% sucrose overnight at 4°C before being embedded
in OCT (Tissue-Tek) for cryosectioning. Human heart samples were
from LV free wall plugs excised during LV assist device implantation or
at the time of cardiac transplantation. Excised tissue was immediately
embedded in OCT and frozen for cryosectioning. Sections of freshfrozen tissue were fixed in 4% paraformaldehyde for 5 minutes at room
temperature before being processed for staining. Sections (7 μm thick)
were incubated in blocking buffer containing TBS, 5% goat serum, and
0.2% Triton X-100 for 2 hours. For IHC employing anti-αSMA antibody (MilliporeSigma, A2547, 1:200), anti-periostin antibody (Novus,
NBP1-300421, 1:200), anti-vimentin (Abcam, ab45939, 1:200), or
anti-Ki67 antibody (Cell Signaling Technology, 9129S, 1:200) antigen
retrieval was performed by heating sections in citrate buffer (pH 6.0)
for 20 minutes before blocking. Blocked sections were incubated in
primary antibodies diluted in blocking buffer overnight at 4°C, rinsed
3 times in TBS containing 0.2% Triton X-100, and then incubated in
appropriate fluorophore-conjugated secondary antibodies diluted in
blocking buffer for 1 hour at room temperature. Sections were then
rinsed 3 times in TBS containing 0.2% Triton X-100 and mounted in
2140
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a mounting medium containing DAPI. Images were captured using
an inverted Nikon A1R confocal microscope using NIS Elements AR
4.13 software. Additional primary antibodies and dilutions used in
IHC included the following: anti-EGFP (Abcam, ab290, 1:200), anti–
β-galactosidase (Abcam, ab9361, 1:200), anti-Col1 (Abcam, ab34710,
1:200), anti-Col3 (Abcam, ab7778, 1:200), anti-CD45 (eBioscience,
14-0451-82, 1:50), anti-CD31 (BD Bioscience, 553370, 1:100), antiChad antibody (MilliporeSigma, HPA018241, 1:100), and anti-Comp
antibody (ProteinTech, 13641-1-ap, 1:100). Secondary antibodies
were used at 1:500 dilution in IHC. These included goat anti-mouse
IgG2a Alexa Fluor 568 (Life Technologies, A-21134), goat anti-chicken
Alexa Fluor 488 (Life Technologies, A-11039), goat anti-chicken Alexa
Fluor 568 (Life Technologies, A-11041), goat anti-rabbit Alexa Fluor
488 (Life Technologies, A-11008), and goat anti-rabbit Alexa Fluor
568 (Life Technologies, A-11036).
Identification and quantification of cardiac fibroblasts in IHC staining. Longitudinal sections containing the core infarct regions were
used for IHC staining and quantification analysis. EGFP+ cells with
nuclei identified by DAPI staining were counted as lineage-traced
cardiac fibroblasts and were included in the analysis. For each heart
sample, the total number of cardiac fibroblasts on 4 randomly selected
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Figure 11. Representative mouse and human
heart IHC of selected proteins underlying
the matrifibrocyte. (A) Representative IHC
heart images showing Comp protein expression (red) along with Tcf21 lineage–traced
(EGFP+) fibroblasts from uninjured mice or
the infarct region 7 and 28 days after MI.
Nuclei are shown with DAPI (blue). Scale bars:
20 μm. (B) Representative IHC mouse heart
images showing Chad protein expression
(red) along with Tcf21 lineage–traced (EGFP+)
fibroblasts from uninjured heart or the infarct
region 7 and 28 days after MI. Nuclei are
shown with DAPI (blue). The insets show
higher magnification (×4) of double-positive
cell for EGFP and Chad. Scale bars: 20 μm. (C)
Representative IHC images showing protein
expression of Chad (red), Comp (red), αSMA
(red), Col3 (red), or vimentin (Vim, green)
on the same or adjacent serial sections of
ischemic LV human heart samples with scar
and/or uninjured (control). Nuclei are shown
with DAPI (blue). n = 3 (ischemic LVAD). n = 1
(healthy control). Scale bars: 20 μm.

microscopic fields of each of 3 stained sections at various depths representing the entire infarct region was counted (4 fields per section,
3 sections per heart). The data from 3 independent sections for each
biological sample were averaged for comparison. Mice were randomly
assigned to experimental groups. Experiments were performed in a
blinded manner where possible.

Picrosirius red staining. Picrosirius red staining was carried out as
previously described (54). Briefly, longitudinal heart sections were collected from frozen samples and incubated in Bouin’s fixative (Electron
Microscopy Sciences, 26367-01) for 1 hour at 55°C and then stained
with Picrosirius red (Electron Microscopy Science, 26357-02) for
1 hour at room temperature. Sections were subsequently dehydrated
jci.org   Volume 128   Number 5   May 2018
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and cleared with xylene. Pictures were captured in bright-field mode
or under polarized light to capture the birefringence of collagen fibers
using an Olympus light microscope.
Statistics. All data are expressed as mean ± SEM unless otherwise
stated. Data were analyzed using GraphPad Prism 7 (GraphPad Software, Inc.). One-way ANOVA with post hoc Tukey’s test was used to
determine the significance of difference when more than 2 groups
were compared. Two-tailed t test was used to determine significance
of differences among means when only 2 groups were compared.
P < 0.05 was considered significant.
Study approval. All experiments involving mice were approved
by the IACUC at CCHMC (approval number IACUC 2016-0069).
Experimentation with human tissue was performed in accordance with
NIH and HIPAA guidelines under an approved Institutional Review
Board protocol (2013-1386 of CCHMC to Burns Blaxall). Patients gave
informed consent.
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